Context Therapeutics (NASDAQ:CNTX) Shares Down 6.4%

Context Therapeutics Inc. (NASDAQ:CNTX)’s share price traded down 6.4% during mid-day trading on Friday . The company traded as low as $1.32 and last traded at $1.32. 5,702 shares were traded during mid-day trading, a decline of 89% from the average session volume of 53,032 shares. The stock had previously closed at $1.41.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright dropped their price target on shares of Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, March 21st.

Context Therapeutics Trading Down 6.4 %

The firm’s 50 day simple moving average is $1.22 and its 200-day simple moving average is $1.12.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.07). Sell-side analysts forecast that Context Therapeutics Inc. will post -1.38 earnings per share for the current year.

Institutional Investors Weigh In On Context Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its stake in Context Therapeutics by 47.4% during the 2nd quarter. Renaissance Technologies LLC now owns 28,300 shares of the company’s stock worth $45,000 after purchasing an additional 9,100 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Context Therapeutics by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 640,699 shares of the company’s stock valued at $711,000 after acquiring an additional 11,720 shares during the last quarter. State Street Corp boosted its position in shares of Context Therapeutics by 79.8% during the 3rd quarter. State Street Corp now owns 32,907 shares of the company’s stock valued at $37,000 after acquiring an additional 14,607 shares during the last quarter. Northern Trust Corp acquired a new position in shares of Context Therapeutics during the 2nd quarter valued at about $49,000. Finally, Atria Wealth Solutions Inc. acquired a new position in shares of Context Therapeutics during the 2nd quarter valued at about $51,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.